Jornal Vascular Brasileiro
https://www.jvascbras.org/article/doi/10.1590/S1677-54492008000100009
Jornal Vascular Brasileiro
Review Article

Contribuição na prevenção da isquemia cerebral pelo cilostazol, um inibidor da fosfodiesterase III: revisão de literatura

Contribution to prevention of cerebral ischemia by cilostazol, a phosphodiesterase III inhibitor: a review

Marcelo Pereira da Rosa; Gislaine Verginia Baroni; Vera Lúcia Portal

Downloads: 0
Views: 157

Resumo

Esta revisão bibliográfica objetiva expor estas pesquisas sobre as ações do cilostazol no sistema nervoso central. O cilostazol é uma droga que demonstrou exercer inibição seletiva e potente da fosfodiesterase tipo III, ocasionando o aumento de adenosina cíclica -3',5'-monofosfato nas plaquetas, nas células endoteliais e nas células musculares lisas, sendo classificado como vasodilatador, antiagregante plaquetário e antitrombótico. É o fármaco de primeira escolha na claudicação intermitente devido à doença arterial obstrutiva periférica. Além disso, há evidências de que o cilostazol é eficaz no processo aterosclerótico cerebral, promovendo aumento do fluxo e volume sangüíneos e prevenindo infartos, especialmente lacunares e recorrentes, por diminuir a morte celular devido à apoptose e ao estresse oxidativo nas substâncias branca e parda.

Palavras-chave

Inibidores de fosfodiesterase, infarto cerebral, fluxo sangüíneo cerebral, cilostazol

Abstract

This literature review aims at presenting the main possibilities for the clinical application of cilostazol in the central nervous system. Cilostazol, a selective phosphodiesterase type III inhibitor, increases adenosine 3',5'-cyclic monophosphate levels on platelets, endothelial and smooth muscle cells, having vasodilatory, antiplatelet and antithrombotic properties. Currently, it is the first-choice drug for intermittent claudication, due to peripheral occlusive vascular disease. In addition, there is evidence showing that cilostazol is efficacious in cerebral atherosclerotic process, resulting in increase of blood flow and volume and preventing infarctions, especially lacunar and recurrent, since it reduces cellular death due to apoptosis and oxidative stress in white and gray substances.

Keywords

Phosphodiesterase inhibitors, cerebral infarction, cerebral blood flow, cilostazol

References

Deutsch G, Tweedy JR. Cerebral blood flow in severity-matched Alzheimer and multi-infarct patients. Neurology. 1987;37:431-8.

Boone KB, Miller BL, Lesser IM. Neuropsychological correlates of white-matter lesions in healthy elderly subjects: a threshold effect. Arch Neurol. 1992;49:549-54.

Ihara M, Tomimoto H, Kinoshita M. Chronic cerebral hypoperfusion induces MMP-2 but not MMP-9 expression in the microglia and vascular endothelium of white matter. J Cereb Blood Flow Metab. 2001;21:828-34.

Tanaka K, Ogawa N, Asanuma M, Kondo Y, Nomura M. Relationship between cholinergic dysfunction and discrimination learning disabilities in Wistar rats following chronic cerebral hypoperfusion. Brain Res. 1996;729:55-65.

Wakita H, Tomimoto H, Akiguchi I. Axonal damage and demyelination in the white matter after chronic cerebral hypoperfusion in the rat. Brain Res. 2002;924:63-70.

Wakita H, Tomimoto H, Akiguchi I, Lin JX, Miyamoto K, Oka N. A ciclooxygenase-2 inhibitor attenuates white matter damage in chronic cerebral ischemia. Neuroreport. 1999;10:1461-5.

Sawada M, Kondo N, Suzumura A, Marunouchi T. Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res. 1989;491:394-7.

Taupin V, Renno T, Bourbonniere L, Peterson AC, Rodriguez M, Owens T. Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage: microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factor-alpha in the central nervous system. Eur J Immunol. 1997;27:905-13.

Kurumatani T, Kudo T, Ikura Y, Takeda M. White matter changes in the gerbil brain under chronic cerebral hypoperfusion. Stroke. 1998;29:1058-62.

Petito CK, Olarte JP, Roberts B, Nowak TS Jr, Pulsinelli WA. Selective glial vulnerability following transient global ischemia in rat brain. J Neuropathol Exp Neurol. 1998;57:231-8.

Akiguchi I, Tomimoto H, Suenaga T, Wakita H, Budka H. Alterations in glia and axons in the brains of Binswanger's disease patients. Stroke. 1997;28:1423-9.

Tomimoto H, Ihara M, Wakita H. Chronic cerebral hypoperfusion induces white matter lesions and loss of oligodendroglia with DNA fragmentation in the rat. Acta Neuropathol. 2003;106:527-34.

Hollensworth SB, Shen C, Sim JE, Spitz DR, Wilson GL, LeDoux SP. Glial cell type-specific responses to menadione-induced oxidative stress. Free Radic Biol Med. 2000;28:1161-74.

Pantoni L, Garcia JH, Gutierrez JA. Cerebral white matter is highly vulnerable to ischemia. Stroke. 1996;27:1641-6.

Sgonc R, Wick G. Methods for the detection of apoptosis. Int Arch Allergy Immunol. 1994;105:327-32.

Borutaite V, Jekabsone A, Morkuniene R, Brown GC. Inhibition of mitochondrial permeability transition prevents mitochondrial dysfunction, cytochrome c release and apoptosis induced by heart ischemia. J Mol Cell Cardiol. 2003;35:357-66.

Liedtke W, Edelmann W, Bieri PL. GFAP is necessary for the integrity of CNS white matter architecture and long-term maintenance of myelination. Neuron. 1996;17:607-15.

Narita M, Yoshida T, Nakajima M. Direct evidence for spinal cord microglia in the development of a neuropathic pain-like state in mice. J Neurochem. 2006;97:1337-48.

Vogel US, Reynolds R, Thompson RJ, Wilkin GP. Expression of the 2',3'-cyclic nucleotide 3'-phosphohydrolase gene and immunoreactive protein in oligodendrocytes as revealed by in situ hybridization and immunofluorescence. Glia. 1988;1:184-90.

Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13:2905-27.

Allende JE, Allende CC. Protein kinase CK2: an enzyme with multiple substrates and a puzzling regulation. FASEB J. 1995;9:313-23.

Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science. 1998;280:1614-7.

Walton MR, Dragunow I. Is CREB a key to neuronal survival?. Trends Neurosci. 2000;23:48-53.

Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol. 2002;90:1314-9.

Regensteiner JG, Ware JE Jr., McCarthy WJ. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc. 2002;50:1939-46.

Hirsch AT, Haskal ZJ, Hertzer NR. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113:e463-654.

Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung. 1985;35:1144-9.

Yasuda K, Sakuma M, Tanabe T. Hemodynamic effect of cilostazol on increasing peripheral blood flow in arteriosclerosis obliterans. Arzneimittelforschung. 1985;35:1198-200.

Kim JS, Lee KS, Kim , Tamai Y, Nakahata R, Takami H. A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: analysis with quantitative bleeding time and platelet aggregation test. J Clin Neurosci. 2004;11:600-2.

Tamai Y, Takami H, Nakahata R, Ono F, Munakata A. Comparison of the effects of acetylsalicylic acid, ticlopidine and cilostazol on primary hemostasis using a quantitative bleeding time test apparatus. Haemostasis. 1999;29:269-76.

Shrör K. The pharmacology of cilostazol. Diabetes Obes Metab. 2002;4(^s2):S14-9.

Katakami Y, Nakao Y, Koizumi T, Katakami N, Ogawa R, Fujita T. Regulation of tumour necrosis factor production by mouse peritoneal macrophages: the role of cellular cyclic AMP. Immunology. 1988;64:719-24.

Park SY, Lee JH, Kim CD. Cilostazol suppressed superoxide production and expression of adhesion molecules in human endothelial cells via mediation of cAMP-dependent protein kinase-mediated Maxi-K channel activation. J Pharmacol Exp Ther. 2006;317:1238-45.

Kohda N, Tani T, Nakayama S. Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. Thromb Res. 1999;96:261-8.

Ahn CW, Lee HC, Park SW. Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2001;52:45-53.

Caplan LR. Antiplatelet therapy in stroke prevention: present and future. Cerebrovasc Dis. 2006;21(^s1):1-6.

Sorkin EM, Markham A. Cilostazol. Drugs Aging. 1999;14:63-71.

Beebe HG, Dawson DL, Cutler BS. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med. 1999;159:2041-50.

Money SR, Herd JA, Isaacsohn JL. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg. 1998;27:267-74.

Bramer SL, Forbes WP. Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazol. Clin Pharmacokinet. 1999;37(^s2):25-32.

Regensteiner JG, Hiatt WR. Current medical therapies for patients with peripheral arterial disease: a critical review. Am J Med. 2002;112:49-57.

Mukherjee D, Yadav JS. Update on peripheral vascular diseases: from smoking cessation to stenting. Cleve Clin J Med. 2001;68:723-33.

Lee JH, Lee YK, Ishikawa M. Cilostazol reduces brain lesion induced by focal cerebral ischemia in rats: an MRI study. Brain Res. 2003;994:91-8.

Watanabe T, Zhang N, Liu M, Tanaka R, Mizuno Y, Urabe T. Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion. Stroke. 2006;37:1539-45.

Honda F, Imai H, Ishikawa M. Cilostazol attenuates gray and white matter damage in a rodent model of focal cerebral ischemia. Stroke. 2006;37:223-8.

Birk S, Kruuse C, Petersen KA, Jonassen O, Tfelt-Hansen P, Olesen J. The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. J Cereb Blood Flow Metab. 2004;24:1352-8.

Birk S, Edvinsson L, Olesen J, Kruuse C. Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries. Eur J Pharmacol. 2004;489:93-100.

Nakamura K, Ikomi F, Ohhashi T. Cilostazol, an inhibitor of type 3 phosphodiesterase, produces endothelium-independent vasodilation in pressurized rabbit cerebral penetrating arterioles. J Vasc Res. 2006;43:86-94.

Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991;337:1521-6.

Tanaka K, Gotoh F, Fukuuchi Y. Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia. Stroke. 1989.

Lee JH, Park SY, Shin YW. Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion. Brain Res. 2006;1082:182-91.

Chen J, Graham SH, Nakayama M. Apoptosis repressor genes Bcl-2 and Bcl-x-long are expressed in the rat brain following global ischemia. J Cereb Blood Flow Metab. 1997;17:2-10.

Choi JM, Shin HK, Kim KY, Lee JH, Hong KW. Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats. J Pharmacol Exp Ther. 2002;300:787-93.

Hong KW, Lee JH, Kima KY, Park SY, Lee WS. Cilostazol: therapeutic potential against focal cerebral ischemic damage. Curr Pharm Des. 2006;12:565-73.

Hong KW, Kim KY, Shin HK. Cilostazol prevents tumor necrosis factor-alpha +-induced cell death by suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation and activation of akt/cyclic AMP response element-binding protein phosphorylation. J Pharmacol Exp Ther. 2003;306:1182-90.

Lee JH, Kim KY, Lee Y. Cilostazol prevents focal cerebral ischemic injury by enhancing casein kinase 2 phosphorylation and suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation in rats. J Pharmacol Exp Ther. 2004;308:896-903.

Wu S, Liu S, Huang M. Cilostazol, an inhibitor of type 3 phosphodiesterase, stimulates large-conductance, calcium-activated potassium channels in pituitary GH³: cells and pheochromocytoma PC12 cells. Endocrinology. 2004;145:1175-84.

Zhu L, Ling S, Yu XD. Modulation of mitochondrial Ca2 homeostasis by Bcl-2. J Biol Chem. 1999;274:33267-73.

Lee JH, Park SY, Lee WS, Hong KW. Lack of antiapoptotic effects of antiplatelet drug, aspirin and clopidogrel, and antioxidant, MCI-186, against focal ischemic brain damage in rats. Neurol Res. 2005;27:483-92.

Kwon SU, Cho YJ, Koo JS. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke. 2005;36:782-6.

Gotoh F, Tohgi H, Hirai S. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis. 2000;9:147-57.

Matsumoto M. Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study. Atheroscler Suppl. 2005;6:33-40.

Inoue T, Kobayashi M, Uetsuka Y, Uchiyama S. Pharmacoeconomic analysis of cilostazol for the secondary prevention of cerebral infarction. Circ J. 2006;70:453-8.

Mochizuki Y, Oishi M, Mizutani T. Effects of cilostazol on cerebral blood flow, P300, and serum lipid levels in the chronic stage of cerebral infarction. J Stroke Cerebrovasc Dis. 2001;10:63-9.

Oishi M, Mochizuki Y, Shikata E, Satoh Y. Effect of cilostazol on cerebral blood flows in chronic stage of cerebral circulation. Keio J Med. 2000;49(^s1):A145-7.

Kobayashi S, Yamaguchi S, Katsube T, Kitani M, Okada K, Tsunematsu Y. Long-term effect of cilostazol on cerebral blood flow in chronic cerebral infarction. Arzneimittelforschung. 1985;35:1193-7.

5ddd75990e8825fe081da3e9 jvb Articles

J Vasc Bras

Share this page
Page Sections